🔥🐔 BizChicken 🐔🔥

Companies Similar to Neumora Therapeutics, Inc. Common Stock

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Athira Pharma, Inc.

Athira Pharma, Inc. logo
Market Cap: Lowest
Employees: Low

ATH-1017

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.

Tags: Alzheimer's disease, Parkinson's disease, biopharmaceutical, clinical trials, neurodegeneration

Symbol: ATHA

Recent Price: $0.55

Industry: Biotechnology

CEO: Dr. Mark J. Litton M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 18706 North Creek Parkway, Bothell, WA 98011

Phone: 425 620 8501

Last updated: 2024-12-31

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CAP-1002

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.

Tags: COVID-19, Duchenne muscular dystrophy, biotechnology, cell therapy, therapeutics

Symbol: CAPR

Recent Price: $13.76

Industry: Biotechnology

CEO: Dr. Linda Marbán Ph.D.

Sector: Healthcare

Employees: 101

Address: 10865 Road to the Cure, San Diego, CA 92121

Phone: 310 358 3200

Leadership

  • Linda Marbán, Ph.D., Chief Executive Officer and Director
  • Kristi A. H. Elliott, Ph.D., Chief Science Officer
  • AJ Bergmann, M.B.A., Chief Financial Officer
  • Karen G. Krasney, J.D., Executive Vice President and General Counsel
  • Mark Awadalla, Vice President of Clinical Operations
  • Jonathan Tayco, Vice President of Program Management and Business Operations
  • Minghao Sun, Ph.D., Vice President of Research and Product Development
  • Yushi Feng, Ph.D., Vice President of Regulatory Affairs
  • Frank Litvack M.D., FACC, Executive Chairman
  • Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
  • Earl M. (Duke) Collier Jr., Director
  • George W. Dunbar, Jr., Director
  • Philip J. Gotwals, Ph.D., Director
  • Michael Kelliher, Director
  • David B. Musket, Director
  • Karimah Es Sabar, Director

Last updated: 2024-12-31

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. logo
Market Cap: Highest
Employees: Medium

INGREZZA

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for various conditions, focusing on innovative solutions for unmet medical needs.

Tags: Parkinson's disease, endocrine disorders, endometriosis, neurology, pharmaceuticals, psychiatric disorders, tardive dyskinesia, uterine fibroids

Symbol: NBIX

Recent Price: $137.06

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Kyle W. Gano Ph.D.

Sector: Healthcare

Employees: 1700

Address: 12780 El Camino Real, San Diego, CA 92130

Phone: 858 617 7600

Last updated: 2024-12-31

Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock logo
Market Cap: High
Employees: Low

navacaprant (NMRA-140)

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Key programs include navacaprant for major depressive disorder, and several promising treatments in various stages of clinical and preclinical trials targeting conditions such as Alzheimer's, schizophrenia, and Parkinson's disease.

Tags: biopharmaceutical, brain diseases, clinical trials, neurodegenerative diseases, neuropsychiatric disorders

Symbol: NMRA

Recent Price: $11.06

Industry: Biotechnology

CEO: Mr. Henry O. Gosebruch

Sector: Healthcare

Employees: 108

Address: 490 Arsenal Way, Watertown, null 02472

Phone: 857 760 0900

Last updated: 2024-12-31

Alzamend Neuro, Inc.

Alzamend Neuro, Inc. logo
Market Cap: Lowest
Employees: Lowest

AL001 and AL002

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing products for neurodegenerative and psychiatric disorders. Their pipeline includes AL001 for Alzheimer's and psychiatric disorders, and AL002 for Alzheimer's disease using a novel vaccine approach.

Tags: Alzheimer's, biopharmaceutical, clinical trials, mental health, neurodegenerative disorders, psychiatric disorders

Symbol: ALZN

Recent Price: $1.20

Industry: Biotechnology

CEO: Mr. Stephan Jackman

Sector: Healthcare

Employees: 4

Address: 3500 Lenox Road NE, Atlanta, GA 30326

Phone: 844 722 6333

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

CervoMed Inc.

CervoMed Inc. logo
Market Cap: Low
Employees: Lowest

neflamapimod

Cervo Med Inc. is a clinical-stage biotechnology company focused on developing and commercializing drug treatments for neurodegenerative diseases, including neflamapimod for conditions like dementia with Lewy bodies, Alzheimer's diseases, and brain stroke recovery.

Tags: Alzheimer's, biotechnology, brain stroke recovery, dementia, drug development, neurodegenerative diseases

Symbol: CRVO

Recent Price: $2.39

Industry: Biotechnology

CEO: Dr. John J. Alam M.D.

Sector: Healthcare

Employees: 8

Address: 20 Park Plaza, Boston, MA 02116

Phone: 617-744-4400

Last updated: 2024-12-31

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. logo
Market Cap: Highest
Employees: Medium

CAPLYTA

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.

Tags: biopharmaceutical, bipolar depression, central nervous system, drug development, neurologic diseases, neuropsychiatric, schizophrenia

Symbol: ITCI

Recent Price: $83.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. Sharon Mates Ph.D.

Sector: Healthcare

Employees: 610

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 440 9333

Leadership

  • Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
  • Michael I. Halstead, J.D., President
  • Mark Neumann, Executive Vice President, Chief Commercial Officer
  • Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
  • Sanjeev Narula, Executive Vice President, Chief Financial Officer
  • John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
  • Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
  • Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
  • Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
  • Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
  • Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
  • Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
  • Rory B. Riggs, MBA, Co-Founder and Director
  • E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
  • Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals

Last updated: 2024-12-31

Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

Roluperidone

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system diseases, including schizophrenia and Parkinson's disease.

Tags: Parkinson's disease, biopharmaceutical, central nervous system, neurodegenerative disorders, schizophrenia

Symbol: NERV

Recent Price: $2.29

Industry: Biotechnology

CEO: Dr. Remy Luthringer Ph.D.

Sector: Healthcare

Employees: 9

Address: 1601 Trapelo Road, Waltham, MA 02451

Phone: 617 600 7373

Leadership

  • Remy Luthringer, PhD, Executive Chairman of the Board, Chief Executive Officer
  • Geoff Race, FCMA, MBA, President
  • Michael Davidson, M.D., Chief Medical Officer
  • Frederick Ahlholm, CPA, Chief Financial Officer
  • Joseph Reilly, Senior Vice President and Chief Operating Officer
  • Jay Saoud, PhD, Consultant
  • Hans Peter Hasler, Board Member
  • Jan van Heek, Board Member
  • David Kupfer, MD, Board Member
  • Fouzia Laghrissi-Thode, MD, Board Member, Chief Executive Officer of DalCor Pharmaceuticals

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

REGENXBIO Inc.

REGENXBIO Inc. logo
Market Cap: Medium
Employees: Medium

NAV Technology Platform

REGENXBIO Inc. is a biotechnology company focusing on gene therapy product candidates to treat genetic defects and enable therapeutic protein production, using its proprietary NAV Technology Platform. Its lead candidate, RGX-314, is in Phase III trials for wet age-related macular degeneration.

Tags: Biotechnology, Clinical Trials, Gene Therapy, NAV Technology Platform, Therapeutic Proteins

Symbol: RGNX

Recent Price: $7.23

Industry: Biotechnology

CEO: Mr. Curran M. Simpson M.S.

Sector: Healthcare

Employees: 344

Address: 9804 Medical Center Drive, Rockville, MD 20850

Phone: 240 552 8181

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Pro Neura

Titan Pharmaceuticals, Inc. is a pharmaceutical company developing therapeutics for chronic diseases utilizing the Pro Neura drug delivery platform. Its products include the Probuphine implant for opioid use disorder treatment, among other programs for chronic pruritus, opioid relapse prevention, HIV prevention, and contraception.

Tags: HIV prevention, Pro Neura, chronic diseases, contraception, drug delivery, opioid use disorder, pharmaceutical, therapeutics

Symbol: TTNP

Recent Price: $3.40

Industry: Biotechnology

CEO: Jennifer Kiernan

Sector: Healthcare

Employees: 4

Address: 400 Oyster Point Boulevard, South San Francisco, CA 94080-1958

Phone: 650 244 4990

Leadership

  • Dato’ Seow Gim Shen, Chief Executive Officer and Chairman of the Board of Directors
  • Avraham Ben-Tzvi, Founder
  • Brynner Chiam, Vice President of Finance and Tax
  • Firdauz Edmin Bin Mokhtar, Chief Executive Officer
  • Francisco Osvaldo Flores García, Managing Partner

Last updated: 2024-12-31

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. logo
Market Cap: Medium
Employees: Low

RNA medicines

Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious and rare diseases, including programs for cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates with various partners for vaccine and therapeutic development.

Tags: RNA medicines, collaborations, infectious diseases, rare diseases, vaccines

Symbol: ARCT

Recent Price: $16.58

Industry: Biotechnology

CEO: Mr. Joseph E. Payne M.Sc.

Sector: Healthcare

Employees: 180

Address: 10628 Science Center Drive, San Diego, CA 92121

Phone: 858 900 2660

Last updated: 2024-12-31

Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

Tecarfarin

Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company focusing on novel therapies for preventing systemic thromboembolism in patients with specific health conditions, headquartered in Ponte Vedra, Florida.

Tags: Tecarfarin, atrial fibrillation, biopharmaceutical, cardiac, clinical development, end-stage renal disease, orphan drug, systemic thromboembolism

Symbol: CVKD

Recent Price: $14.23

Industry: Biotechnology

CEO: Mr. Quang X. Pham

Sector: Healthcare

Employees: 4

Address: 822 A1A North, Ponte Vedra, FL 32082

Phone: 904 300 0701

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nana-val

Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies, with a lead product candidate Nana-val in clinical trials for Epstein-Barr virus-positive lymphoma and other related conditions.

Tags: EBV+ lymphoma, biotech, clinical trials, oncology, pharmaceuticals, virus-associated malignancies

Symbol: VIRX

Recent Price: $0.16

Industry: Biotechnology

CEO: Mr. Mark Andrew Rothera

Sector: Healthcare

Employees: 40

Address: 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA 92007

Phone: 858 400 8470

Leadership

  • Mark Rothera, President and Chief Executive Officer
  • Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer
  • Ayman Elguindy, Ph.D., Chief Scientific Officer
  • Michael Faerm, MBA, Chief Financial Officer
  • Cheryl Madsen, Senior Vice President, Regulatory
  • Patric Nelson, MBA, Senior Vice President, Business Development & Corporate Strategy
  • Biljana Nadjsombati, Pharm.D., Senior Vice President, Pharmaceutical Development
  • Violetta Akopian, Ph.D., Vice President, Quality Assurance
  • Ruby Cheema, Vice President, Portfolio and Program Management
  • Mark A. McCamish, M.D., Ph.D., Strategic Advisor
  • Roger J. Pomerantz, M.D., Chairman of the Board
  • Jane F. Barlow, M.D., MPH, MBA, Director
  • Flavia Borellini, Ph.D., Director
  • Jane Chung, R.Ph., Director
  • Thomas E. Darcy, CPA, Director
  • Sam Murphy, Ph.D., Director
  • Ivor Royston, M.D., Director
  • Stephen Rubino, Ph.D., MBA, Director
  • Barry J. Simon, M.D., Director
  • Douglas V. Faller, M.D., Ph.D., Scientific Founder and Chairman, Scientific Advisory Board
  • Robert Baiocchi, M.D., Ph.D., Scientific Advisor
  • Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Scientific Advisor
  • Carl June, M.D., Scientific Advisor
  • Shannon Kenney, M.D., Scientific Advisor
  • Ronald Levy, M.D., Scientific Advisor
  • Pierluigi Porcu, M.D., Scientific Advisor
  • Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR, Scientific Advisor
  • Lawrence Young, Ph.D., Scientific Advisor

Last updated: 2024-12-31